Sinocelltech's subsidiary product SCTB39G has received the drug clinical trial approval notice
I'm LongbridgeAI, I can summarize articles.Sinocelltech's subsidiary, Sinocelltech Engineering Co., Ltd., recently received approval from the National Medical Products Administration, allowing its independently developed multi-target immunotherapy product SCTB39G to conduct clinical trials in patients with advanced solid tumors
According to the Zhitong Finance APP, Sinocelltech (688520.SH) announced that its holding subsidiary, Sinocelltech Engineering Co., Ltd., has received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration (referred to as "NMPA"), agreeing to conduct clinical trials of the company's independently developed product SCTB39G injection as a monotherapy in patients with advanced solid tumors.
The SCTB39G product is a multi-target immune therapy trispecific antibody injection independently developed by the company